Initial & continued use approval criteria: Formulary tofacitinib extended release (Xeljanz XR) will be covered on the prescription drug benefit when the following criteria are met:

- Prescriber is a Rheumatologist
  - AND –

- Patient has a diagnosis of rheumatoid arthritis
  - AND –

- Inadequate response or intolerance to one nonbiologic DMARD: methotrexate, sulfasalazine, hydroxychloroquine, leflunomide
  - AND –

- Patient has had a previous trial of Xeljanz immediate release, 5 mg taken twice daily with documented concern about patient’s ability to adhere to twice daily medication dosing and the patient does not take any other medications more than one time a day.
  - OR –

- Prescriber is a Rheumatologist
  - AND –

- Patient has a diagnosis of psoriatic arthritis
  - AND –

- For biologic naïve patients: Inadequate response or intolerance to one nonbiologic DMARD: methotrexate, sulfasalazine, hydroxychloroquine, leflunomide -OR- Patient has had a previous trial of a biologic medication (e.g., adalimumab, certolizumab, etanercept, golimumab, infliximab product, secukinumab, ustekinumab), or apremilast
  - AND –

- Patient has had a previous trial of Xeljanz immediate release, 5 mg taken twice daily with documented concern about patient’s ability to adhere to twice daily medication dosing and the patient does not take any other medications more than one time a day.